FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nuvation Bio's Free Cash Flow for the
three
months ended in Dec. 2024 was $-46.29 Mil. Nuvation Bio's Revenue for the
three
months ended in Dec. 2024 was $5.71 Mil. Therefore, Nuvation Bio's FCF Margin % for the quarter that ended in Dec. 2024 was -810.52%.
The historical rank and industry rank for Nuvation Bio's FCF Margin % or its related term are showing as below:
NUVB'
s FCF Margin % Range Over the Past 10 Years
Min: -1658.52 Med: -1658.52 Max: -1658.52
Current: -1658.52
During the past 5 years, the highest FCF Margin % of Nuvation Bio was -1658.52%. The lowest was -1658.52%. And the median was -1658.52%.
NUVB's FCF Margin % is ranked worse than 81.81% of 1017
companies
in the Biotechnology industry
Industry Median: -142.95
vs NUVB: -1658.52
Nuvation Bio FCF Margin % Historical Data
The historical data trend for Nuvation Bio's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nuvation Bio's FCF Margin %
For the Biotechnology subindustry, Nuvation Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio FCF Margin % Related Terms
Thank you for viewing the detailed overview of Nuvation Bio's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NUVB has been successfully added to your 